Lufotrelvir

N/A

Report date: 2023/03/28 20:00:38
NME

Base Information

Drug NameLufotrelvir
Drug Alias NamePF-07304814
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSARS-CoV-2-3C-like-proteinase inhibitors
TargetsSARS-CoV-2-3C-like-proteinase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Virus Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesDenmark +[5] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer Inc
Inactive CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsVirus Diseases
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A
Related LinksN/A